PATENT CLAIM ANALYSIS

Application Number: 15750318
Application Type: Utility
Filing Date: 2018-02
Publication Date: 2018-08
Patent Classification: ["514", "482000"]

Abstract:
Pharmaceutical compositions for the treatment of cancer are provided. In one embodiment the composition comprises Gamitrinib and a MAPK inhibitor selected from the MAPK inhibitor is selected from RAF265, AZD6244, PLX4720, PD0325901, LGX818, MEK162, vemurafenib, trametinib and dabrafenib. Methods of treating cancer are also provided.

Claim (Index 40):
A method of treating cancer, comprising\n (i) measuring the level of expression of one or more mitobiogenesis biomarker listed in Table 1 using the composition of  claim 17 ; (ii) comparing levels with the level of the same biomarker in a control sample, and (iii)(a) where the level of expression of one or more mitobiogenesis biomarkers is higher than the control level, decreasing the amount of MAPK inhibitor as compared to normal regimen; or (iii)(b) where the level of expression of one or more mitobiogenesis biomarkers is lower than the control level, increasing the amount of MAPK inhibitor as compared to normal regimen.

Metadata:
- Claim Count in Document: 48.0
- Percentile: 88.0
- Lexical Diversity: 1.52778
- Patent Class: 514.0
- Transitional Phrase Type: open
- Component Type: 1
- Foreign Priority: False
- Related Applications: ['14770994', '14387735', '14147689', '12865620', '15002457']

Analysis Scores:
- 35 USC 101 Eligibility (BERT): 0.7673547090674255
- 35 USC 102 Novelty (BERT): 0.5365086054599588
- Combined Prediction Score: 0.7442700987066789
- Mean Citation Score: 304.030938
- Max Citation Score: 382.53238
- Similarity Product: 226.7590239713156

Labels:
- Claim Label 101: 1
- Claim Label 102: 1
- Claim Label 103: 1
- Claim Label 112: 1
- Combined Label: 1
- Label 101 Adjusted: 1

Dataset: test